Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008.

scientific article published on 26 June 2009

Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.NMD.2009.05.003
P932PMC publication ID2766092
P698PubMed publication ID19560356
P5875ResearchGate publication ID26324508

P50authorKanneboyina NagarajuQ27662260
P2093author name stringRaffaella Willmann
TREAT-NMD Network and the Wellstone Muscular Dystrophy Cooperative Research Network
P2860cites workPreclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measuresQ33975979
Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyQ36841572
Mammalian animal models for Duchenne muscular dystrophyQ37393140
P433issue7
P921main subjectworkshopQ27556165
P304page(s)502-506
P577publication date2009-06-26
P1433published inNeuromuscular DisordersQ1981326
P1476titleDeveloping standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008.
P478volume19

Reverse relations

cites work (P2860)
Q35583176Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice
Q48133974Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
Q30498131Gait disturbances in dystrophic hamsters
Q89746817Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT)
Q35203141In vivo canine muscle function assay
Q35014916Interventions for muscular dystrophy: molecular medicines entering the clinic
Q37589787Looking Forward to New Therapies: A Personal Perspective on the Translational Landscape for Muscular Dystrophies
Q92464608Micro-dystrophin Gene Therapy Partially Enhances Exercise Capacity in Older Adult mdx Mice
Q39663447Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes
Q90733720Mouse models for muscular dystrophies: an overview
Q28087567Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus
Q34152280Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials
Q92070180QuantiMus: A Machine Learning-Based Approach for High Precision Analysis of Skeletal Muscle Morphology
Q59100459Risks and crises for healthcare providers: the impact of cloud computing
Q35563234SMASH - semi-automatic muscle analysis using segmentation of histology: a MATLAB application.
Q34756106Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.
Q28088277The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development
Q34077151The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice
Q55024154Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands.
Q34981147VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects

Search more.